Hepatocellular Carcinoma (HCC): Recent Updates and Evolving Treatment Paradigms

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

R. Katie Kelley, MD, provides an overview of the first-line systemic treatment options for patients with advanced hepatocellular carcinoma.

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

R. Katie Kelley, MD, discusses updated safety data on tremelimumab plus durvalumab for patients with advanced hepatocellular carcinoma.

Dr R. Katie Kelley explains the design and results of the phase 3 CELESTIAL study investigating single-agent cabozantinib for the treatment of advanced hepatocellular carcinoma.

R. Katie Kelley, MD, comments on the safety and efficacy data from the retrospective analysis of the CELESTIAL study in advanced hepatocellular carcinoma.

Dr R. Katie Kelley highlights other abstracts presented at World GI 2023 and shares what she looks forward to in the future of advanced hepatocellular carcinoma treatment.